ROL' NARUShENIYa KROVOSNABZhENIYa I TKANEVOY GIPOKSII V RAZVITII DISFUNKTsII MOChEVOGO PUZ'ІRYa PRI INFRAVEZIKAL'NOY OBSTRUKTsII, V'ІZVANNOY ADENOMOY PREDSTATEL'NOY ZhELEZ'І


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Full Text

Restricted Access

References

  1. Sibley G.N. A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit. J. Physiol. 1984; 354: 431-443.
  2. Zhou Y., Ling E.A. Nitric oxide syntase - Its distribution and alteration in the intramural ganglia of the urinary bladder in normal and urethra-obstructed guinea pigs. Ann. Acad. Med. Singapore 1999; 28 (1): 49-61.
  3. Pandita R.K., Fujiwara M., Aim P. et al. Cystometric evaluation of bladder function in non-anesthetized mice with and without bladder outlet osstruction. J. Urol. 2000;164(4):1385-1389.
  4. McVary K.T., Rademaker A., Lloyd G.L. et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 2005; 174:1327-1433.
  5. Bajory Z., Szabli A., Kirgyly I., Pajor L. et al. Involvement of nitric oxide in microcirculatory reactions after ischemia-reperfusion of the rat urinary bladder. Eur. Surg. Res. 2009;42(1):28-34.
  6. Shimizu S., Saito M., Kinoshita Y. et al. Acute urinary retention and subsequent catheterization cause lipid peroxidation and oxidative DNA damage in the bladder: preventive effect of edaravone, a free-radical scavenger. BJU Int. 2009;104(5):713-717.
  7. Ohmasa F., Saito M., Shimizu S. et al. The role of ATP-sensitive potassium channel on acute urinary retention and subsequent catheterization in the rat. Eur. J. Pharmacol. 2010; 635(1-3):194-197.
  8. Kershen R.T., Azadzoi K.M., Siroku M.B. Blood flow, pressure and compliance in the male human bladder. J. Urol. 2002; 168(1):121-125.
  9. Мудрая И.С., Ибрагимов А.Р., Кирпатовский В.И. и др. Оценка функционального состояния мочевого пузыря крыс методом Фурье-импедансной цистометрии. экспериментальная и клиническая урология. 2010;3:21-26.
  10. Schroder A., Chichester P., Kogan B.A. et al. Effect of bladder outlet obstruction on blood flow of the rabbit bladder. J. Urol. 2001;165(2):640—646.
  11. Shabsigh A., Hayek O.R., Weiner D. et al. Acute increase in blood flow to the rat bladder subsequent to partial bladder outlet obstruction. Neurourol. Urodyn. 2000;19(2):195-206.
  12. Chichester P., Lieb J., Levin S.S. et al. Vascular response of rabbit bladder to short term partial outlet obstruction. Mol. Cell Biochem. 2000;208(1—2):19—26.
  13. Matsumoto S., Uemura H. Examination of the mechanism of ameliorating effect of alpha 1-blocker on storage symptoms associated with benign prostatic hyperplasia. Hinyokika Kiyo 2008;54(6):453—456.
  14. Okutsu H., Matsumoto S., Hanai T. et al. Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction. Urology 2010;75(1):235—240.
  15. Azadzoi K.M. Effect of chronic ischemia on bladder structure and function. Adv Exp Med Biol 2003; 539 (Pt A): 271-280.
  16. Azadzoi K.M., Heim V.K., Tarkan T. et al. Alteration of urothelial-mediated tone in the ischemic bladder: role of eicosanids. Neurourol. Urodyn. 2004;23(3):258-264.
  17. Yamaguchi O., Aikawa K., Shishido K. et al. Place of overactive bladder in male lower urinary tract symptoms. World J Urol. 2009 Aug 25. [Epub ahead of print].
  18. Mitterberger M., Pallwein L., Gradl J. et al. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU Int. 2007; 99(4):831-835.
  19. Scheepe J.R., Amelink A., Wolffenbuttel K.P. et al. Changes in bladder wall perfusion in the overactive obstructed bladder. Eur. Urol. 2010;9(Suppl. 2):114.
  20. Вишневский Е.Л., Лоран О.Б., Пушкарь Д.Ю. и др. Обструктивная ноктурия. М.: АНМИ, 2007; 162.
  21. Polyanska M., Arner A., Malmquist U. et al. Lactate dehydrogenase activity and isoform distribution in the rat urinary bladder: effect of outlet obstruction and its removal. J. Urol. 1993; 150(2, Pt 1):543—545.
  22. Azadzoi K.M., Radisavljevic Z.M., Golabek T. et al. Oxidative modification of mitochondrial integrity and nerve fiber density in the ischemic overactive bladder. J. Urol. 2010;183(1):362—369.
  23. Bean H., Radu F., De E., Schuler C. et al. Comparative evaluation of antioxidant reactivity within obstructed and control rabbit urinary bladder tissue using FRAP and CUPRAC assays. Mol. Cell. Biochem. 2009;323(1—2):139—142.
  24. Hass M.A., Leonova E., Levin R.M. Fatty acid profiles in normal and obstructed rabbit bladder smooth muscle and mucosa. Neurourol. Urodyn. 1999;18(6):697—711.
  25. O'Connor L.J., Goldner C.W., Lau S.T. et al. Effect of partial outflow obstruction on the distribution of free fatty acids and phospholipids in the rabbit bladder. World J. Int. 1999;17(5):261—265.
  26. Ghafar M.A., Anastasiadis A.G., Olsson L.E. et al. Hypoxia and angiogenic response in the partially obstructed rat bladder. Lab. Invest. 2002;82(7):903—909.
  27. Koritsiadis G., Tyritzis S.I., Koutalellis G. et al. The effect of alphablocker treatment on bladder hypoxia inducible factor-1 alpha regulation during lower urinary tract obstruction. Int. Braz. J. Urol. 2010;36(1):86—94.
  28. Ramchandren S., Liebeskind D.S. Neurogenic bladder due to hypoxic-ischemic demyelination. J. Neuroimaging. 2008;18(2):198—201.
  29. Azadzoi K.M., Yalla S.V., Siroky M.B. Oxidative stress and neurodegeneration in the ischemic overactive bladder. J. Urol. 2007;178(2):710—715.
  30. Azadzoi K.M., Radisavljevic Z.M., Siroky M.B. Effects of ischemia on tachykinin-containing nerves and neurokinin receptors in the rabbit bladder. Urology. 2008;71(5):979—983.
  31. Juan Y.S., Chuang S.M., Kogan B.A. et al. Effect of ischemia/ reperfusion on bladder nerve and detrusor cell damage. Int. Urol. Nephrol. 2009;41(3):513—521.
  32. Masuda H., Kihara K., Saito K. et al. Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int. 2008;101(6):775—780.
  33. Morelli A., Filippi S., Comeglio P. et al. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J. Sex. Med. 2010;7(1 Pt 1):107—120.
  34. Dahmani L., Bruyere F., Quaki F. et al. Consequences de l'obstruction infravesicale sur le metabolismeenergetique des cellules musculaires du detrusor. Progr. Urol. 2002;12(4):569—574.
  35. Кирпатовский В.И., Кудрявцев Ю.В., Мудрая И.С. и др. Гетерогенность морфологических и функциональных изменений разных отделов мочевого пузыря крыс при инфравезикальной обструкции мочевих путей. Бюл. экспер. биол. мед. 2009;147(1):108—112.
  36. Li S., Juan Y.S., Kogan B.A. et al. Effects of inosine on response to in vitro hypoxia in absence of substrate on bladder dysfunction in adult rats. Urology. 2009;73(3):661—664.
  37. Лопаткин Н.А., Перепанова Т.С. Клинический опыт лечения больных доброкачественной гиперплазией предстательной железы альфа1-адреноблокатором альфузозином. Урол. нефрол. 1997;5:14.
  38. Лопаткин Н.В. Доброкачественная гиперплазия предстательной железы. М.;1999:216.
  39. Винаров А.З. Медикаментозное лечение больных гиперплазией предстательной желези. Фундаментальние исследования в уронефрологии. Материали Российской научн. конф. Саратов, 2009. 63—70 с.
  40. Сивков А.В. Медикаментозная терапия доброкачественной гиперплазии предстательной желези. В кн. Доброкачественная гиперплазия предстательной желези. Под ред. Н.А. Лопаткина. М.; 1999. 91—116 с.
  41. Mizuno H., Yamamoto T., Okutsu H. et al. Effect of tamsulosin on bladder microcirculation in a rat ischemia-reperfusion model, evaluated by pencil lens charge-coupled device microscopy system. Urology. 2010;76(5):1266.
  42. Лоран О.Б., Вишневский Е.Л., Вишневский А.Е. Лечение расстройств мочеиспускания у больных доброкачественной гиперплазией простаты а1-адреноблокаторами. М.; 1998:124.
  43. Вишневский А.Е., Степанова Н.А., Михайлова Е.В. Сосудистые зффекты альфа1-адреноблокаторов и их клиническое значение у больных доброкачественной гиперплазией простаты. Клиническая фармакология и терапия. 2004;4:90.
  44. Вишневский А.Е. Нарушение знергетического метаболизма в патогенезе расстройств мочеиспускания у больных доброкачественной гиперплазией простаты и обоснование их медикаментозного лечения. Дисс. докт. мед. наук. 2007.
  45. Yono M., Yamamoto Y., Imanishi A. et al. Differential effects of prazosin and naftopidil on pelvic blood flow and nitric oxide synthase levels in spontaneously hypertensive rats. J. Recept. Signal. Transduct. Res. 2008;28(4):403—412.
  46. Martin C.M. Potential role of a1-adrenoceptors in the aetiology of LUTS. Eur. Urol. 2002;3(6 Suppl.):5—13.
  47. Мазо Е.Б. Фармакотерапия доброкачественной гиперплазии простаты. Consilium medicum. 2003;5(7):292.
  48. Sairam K., Kulinskaya E., McNicholas T.A. et al. Sildenafil improves lower urinary tract symptoms. BJU Int. 2002;90:836—839.
  49. Mulhall J.P., Guhring P., Parker M. et al. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J. Sex. Med. 2006;3:662—667.
  50. McVary K.T., Monning W., Camps J.L. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized double-blind trial. J. Urol. 2007;177:1071—1077.
  51. McVary K.T., Roehrborn C.G., Kaminetsky J.C. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 2007;177:1401—1407.
  52. Stief C.G., Porst H., Neuser D. et al. A randomized placebo-control study to assess the efficiency of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur. Urol. 2008;53:1236—1244.
  53. Roehrborn C.G., McVary K.T., Elion-Mboussa A. et al. Tadalafil administrated once daily foe lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J. Urol. 2008;180:1228—1234.
  54. Giuliano F. Mechanism of action of PDE5 inhibitors in LUTS and ED: the NO-cGMP pathway. Eur. Urol. 2009;55:49—51.
  55. Сивков А.В., Кешишев Н.Г., Ковченко Г.А. Влияние ингибиторов фосфодизстеразы 5 типа на симптоми нижних мочевих путей и зректильную функцию у больных ДГПЖ. Экспериментальная и клиническая урология. 2010;4:44—49.
  56. Kohler T.S., McVary K.T. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur. Urol. 2009;55:38—48.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies